Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 13;6(4):e17520.
doi: 10.1371/journal.pone.0017520.

Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010

Balvinder Rehal  1 , April W Armstrong
Affiliations

Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010

Balvinder Rehal et al. PLoS One. .

Erratum in

  • PLoS One. 2011;6(6): 10.1371/annotation/6d5e99c5-bd8f-4cef-b77a-fbb795633da0.. Armstrong, April [Corrected to Armstrong, April W].

Abstract

Background: A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopic dermatitis (AD) in the last decade.

Objectives: To identify trends in outcomes instruments used in AD clinical trials and to provide a useful summary of the dimensions and validation studies for the most commonly used measures.

Method: All randomized control trials (RCTs) from 1985 to 2010 in the treatment of AD were examined.

Results: Among the 791 RCTs reviewed, we identified 20 disease-severity and 14 QoL instruments. Of these outcomes instruments, few have been validated. SCORAD, EASI, IGA and SASSAD were the most commonly used disease-severity instruments and CDLQI, DFI, DLQI and IDQOL were the most frequently used QoL measures.

Limitations: The small number of RCTs using QoL scales makes identifying trends for QoL instruments difficult.

Conclusion: Overall, there is an increase in the use of disease-severity and QoL instruments in AD clinical trials.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Excluded studies.
Figure 2
Figure 2. Trends in Disease Severity Instruments 1985–2010.
Figure 3
Figure 3. Trends in Quality of Life Instruments 1985–2010.
See this image and copyright information in PMC

References

    1. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol. 2006;154:719–725. - PubMed
    1. Chamlin SL, Frieden IJ, Williams ML, Chren MM. Effects of atopic dermatitis on young American children and their families. Pediatrics. 2004;114:607–611. - PubMed
    1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta derm venereol (Stockh) 1980:44–47.
    1. Dohil MA, Eichenfield LF. A treatment approach for atopic dermatitis. Pediatr Ann. 2005;34:201–210. - PubMed
    1. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg. 1998;17:291–296. - PubMed